Sector Update: Healthcare

By
A A A

Healthcare shares are flat to higher in pre-market trade.

Amicus Therapeutics ( FOLD ), a biopharmaceutical company engaged in therapies for rare and orphan diseases, has entered a collaboration with Biogen Idec ( BIIB ) to discover, develop and commercialize novel small molecules for the treatment of Parkinson's disease.

FOLD is up 19% at $3.03 in pre-market trade; BIIB is up 0.7% at $230.50.

The collaboration will build upon preclinical studies at Amicus and independent published research that suggest increasing activity of the lysosomal enzyme glucocerobrosidase in the brain may correct alpha-synuclein pathology and other deficits associated with Parkinson's disease.

And NuPathe ( PATH ) says it received a U.S. patent related to its iontophoretic patch that uses a two-stage delivery sequence to transdermally deliver sumatriptan. This, and other proprietary technology, is incorporated into PATH's lead product, ZECUITY, the first and only FDA approved patch for migraine. PATH is flat at $2.59 in pre-market trade.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks: BIIB , FOLD , PATH

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

Stocks

Referenced

Most Active by Volume

36,586,989
  • $41.35 ▼ 2.29%
33,435,019
  • $42.20 ▼ 10.86%
31,919,424
  • $9.72 ▼ 8.30%
30,045,396
  • $26.49 ▼ 1.41%
29,014,873
  • $8.05 ▼ 8%
27,308,018
  • $14.66 ▼ 8.32%
23,704,236
  • $118.93 ▼ 0.06%
23,514,654
  • $17.04 ▼ 0.41%
As of 11/28/2014, 01:06 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com